Claims against Bayer's One-A-Day vitamins proceed in court; Tech glitches in Open Payments database plaguing pharma;

@FiercePharma: Gates Foundation puts $52 million behind CureVac, following Sanofi, Boehringer's lead. FierceVaccines story | Follow @FiercePharma

@EricPFierce: Texas drug compounder corralled by federal injunction. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Should Teva buy Mylan? 'Close call,' analyst says. Report | Follow @CarlyHFierce

> Plaintiffs suing Bayer over its One-A-Day vitamins can proceed with their claims that the products falsely stated they could boost physical energy, but a judge has dismissed similar heart-health and immunity claims. Report

> Medicare officials say some technical glitches in its Open Payments database system are interfering with pharma's ability to file information on financial relationships with doctors and hospitals. Report

> Generics maker Mylan ($MYL) has launched a range of pain-fighting Fentanyl patches in various doses, adding to its current product line in the area. Release

> With an aging population, pharma stocks will make up an increasingly large chunk of equity indices, a top hedge fund executive figures. Report

> The Dutch pension fund of U.S. pharmaceutical company Johnson & Johnson ($JNJ) has completed a transfer to Belgium after a three-year process. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Brain-controlled, robotic prosthetic hand comes closer to simulating reality. Article | Follow @FierceMedDev

@VarunSaxena2: Irish research center wins EU funding to study and develop transdermal delivery methods. More from FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: Some background info on liquid biopsies. More from MIT Technology Review | Follow @EmilyWFierce

> LifeMap CEO: Apple's ($AAPL) ResearchKit 'unshackles science.' More

> Scientists tout positive results for Alzheimer's ultrasound therapy in mice. Article

> Startup raises $3.9M to market device-app combo to calm panic disorder. Report

Biotech News

@FierceBiotech: Acadia craters as takeover buzz is silenced by news of an unexpected NDA delay, CEO exit. Article | Follow @FierceBiotech

@JohnCFierce: 4 of the last Fierce 15 have filed IPOs since last fall. More coming. Hot market, eh? Feature | Follow @JohnCFierce

@DamianFierce: Here's the $ENDP letter to $SLXP's board, pitching a deal that's 74% stock. PDF | Follow @DamianFierce

> Epizyme ($EPZM) retrieves global rights to cancer drug in $110M deal. News

> Neuralstem ($CUR) tanks on cloudy results for its ALS treament. Story

> 23andMe dives into biotech with Genentech R&D star Richard Scheller on board. Report

Vaccines News

> Analyst: Ebola vaccine developers 'need to weigh risks' as cases dwindle. More

> Combo-happy Diamyd launches new diabetes vaccine trial in children. Report

> Smallpox vaccine helps Bavarian Nordic net first full-year profit in 5 years. Story

> Takeda transfers HPV vaccine rights as it continues globalization push. More

> Bharat's $1 rotavirus vaccine rolls out in India to challenge GSK, Merck. Article

Pharma Manufacturing News

> Hikma profits soften as shortages of doxycycline are resolved. Article

> Mylan recalls drug after problem uncovered with Indian supplier. Item

> Texas compounder corralled by federal injunction. More

> Pfizer ($PFE) makes it official, it has reversed its decision to close Irish Lipitor plant. Story

> Manufacturing mess at Johnson & Jonhson ($JNJ) consumer plant results in guilty plea, $20M fine. Report

Pharma Asia News

> AstraZeneca ($AZN) and Singapore's A*STAR ink research pact on complex heart failure syndrome. More

> Biotech in China is built brick-by-brick, but more money would help, BeiGene's Oyler says. Article

> First off the blocks, Natco gets India's regulatory nod for hep C copy. Story

> Japan a lucrative market for endocrine sales, report says. Item

> Glaxo ($GSK) plants a flag in Singapore with CEO Witty on hand. Report

And Finally... Copay info service NeedyMeds has added generics savings programs to its database. Release

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.